{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T12:51:08Z","timestamp":1782478268021,"version":"3.54.5"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T00:00:00Z","timestamp":1779062400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T00:00:00Z","timestamp":1779062400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Urologie"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1007\/s00120-026-02841-4","type":"journal-article","created":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T16:43:46Z","timestamp":1779122626000},"page":"728-736","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Das oligometastasierte hormonsensitive Prostatakarzinom: Wann ist weniger mehr?","Oligometastatic hormone-sensitive prostate cancer: when can less be more?"],"prefix":"10.1007","volume":"65","author":[{"given":"Richard","family":"Cathomas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,18]]},"reference":[{"key":"2841_CR1","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1056\/NEJMoa1503747","volume":"373","author":"CJ Sweeney","year":"2015","unstructured":"Sweeney\u00a0CJ et\u00a0al (2015) Chemohormonal therapy in metastatic hormone-sensitive prostate cancer. N\u00a0Engl J Med 373:737\u2013746","journal-title":"N Engl J Med"},{"key":"2841_CR2","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1056\/NEJMoa1704174","volume":"377","author":"K Fizazi","year":"2017","unstructured":"Fizazi\u00a0K et\u00a0al (2017) Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer. N\u00a0Engl J Med 377:352\u2013360","journal-title":"N Engl J Med"},{"key":"2841_CR3","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1056\/NEJMoa1702900","volume":"377","author":"ND James","year":"2017","unstructured":"James\u00a0ND et\u00a0al (2017) Abiraterone in metastatic prostate cancer. N\u00a0Engl J Med 377:1696\u20131697","journal-title":"N Engl J Med"},{"key":"2841_CR4","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1056\/NEJMoa1903307","volume":"381","author":"KN Chi","year":"2019","unstructured":"Chi\u00a0KN et\u00a0al (2019) Apalutamide for metastatic, castration-sensitive prostate cancer. N\u00a0Engl J Med 381:13\u201324","journal-title":"N Engl J Med"},{"key":"2841_CR5","doi-asserted-by":"publisher","first-page":"2294","DOI":"10.1200\/JCO.20.03488","volume":"39","author":"KN Chi","year":"2021","unstructured":"Chi\u00a0KN et\u00a0al (2021) Apalutamide in patients with metastatic castration-sensitive prostate cancer: Final survival analysis of the randomized, double-blind, phase III TITAN study. J\u00a0Clin Oncol 39:2294\u20132303","journal-title":"J Clin Oncol"},{"issue":"2","key":"2841_CR6","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1056\/NEJMoa1903835","volume":"381","author":"ID Davis","year":"2019","unstructured":"Davis\u00a0ID et\u00a0al (2019) Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer. N\u00a0Engl J Med 381(2):121\u2013131","journal-title":"N Engl J Med"},{"key":"2841_CR7","doi-asserted-by":"publisher","first-page":"2974","DOI":"10.1200\/JCO.19.00799","volume":"37","author":"AJ Armstrong","year":"2019","unstructured":"Armstrong\u00a0AJ et\u00a0al (2019) ARCHES: A Randomized, Phase III Study of Androgen Deprivation Therapy With Enzalutamide or Placebo in Men With Metastatic Hormone-Sensitive Prostate Cancer. J\u00a0Clin Oncol 37:2974\u20132986","journal-title":"J Clin Oncol"},{"key":"2841_CR8","doi-asserted-by":"publisher","first-page":"1616","DOI":"10.1200\/JCO.22.00193","volume":"40","author":"AJ Armstrong","year":"2022","unstructured":"Armstrong\u00a0AJ et\u00a0al (2022) Improved Survival With Enzalutamide in Patients With Metastatic Hormone-Sensitive Prostate Cancer. J\u00a0Clin Oncol 40:1616\u20131622","journal-title":"J Clin Oncol"},{"key":"2841_CR9","doi-asserted-by":"publisher","first-page":"4271","DOI":"10.1200\/JCO-24-01798","volume":"42","author":"F Saad","year":"2024","unstructured":"Saad\u00a0F et\u00a0al (2024) Darolutamide in Combination With Androgen-Deprivation Therapy in Patients With Metastatic Hormone-Sensitive Prostate Cancer From the Phase III ARANOTE Trial. J\u00a0Clin Oncol 42:4271\u20134281","journal-title":"J Clin Oncol"},{"key":"2841_CR10","doi-asserted-by":"publisher","first-page":"1695","DOI":"10.1016\/S0140-6736(22)00367-1","volume":"399","author":"K Fizazi","year":"2022","unstructured":"Fizazi\u00a0K et\u00a0al (2022) Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 232 factorial design. Lancet 399:1695\u20131707","journal-title":"Lancet"},{"key":"2841_CR11","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1056\/NEJMoa2119115","volume":"386","author":"MR Smith","year":"2022","unstructured":"Smith\u00a0MR et\u00a0al (2022) Darolutamide and survival in metastatic, hormone-sensitive prostate cancer. N\u00a0Engl J Med 386:1132\u20131142","journal-title":"N Engl J Med"},{"key":"2841_CR12","doi-asserted-by":"publisher","first-page":"e18","DOI":"10.1016\/S1470-2045(19)30718-1","volume":"21","author":"M Guckenberger","year":"2020","unstructured":"Guckenberger\u00a0M et\u00a0al (2020) Characterisation and classification of oligometastatic disease: a European Society for Radiotherapy and Oncology and European Organisation for Research and Treatment of Cancer Consensus recommendation. Lancet Oncol 21:e18\u2013e28","journal-title":"Lancet Oncol"},{"key":"2841_CR13","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.eururo.2024.09.017","volume":"87","author":"S Gillessen","year":"2025","unstructured":"Gillessen\u00a0S et\u00a0al (2025) Management of Patients with Advanced Prostate Cancer. Report from the 2024 Advanced Prostate Cancer Consensus Conference (APCCC). Eur Urol 87:157\u2013216","journal-title":"Eur Urol"},{"key":"2841_CR14","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/j.eururo.2023.04.002","volume":"84","author":"AJ Armstrong","year":"2023","unstructured":"Armstrong\u00a0AJ et\u00a0al (2023) The Efficacy of Enzalutamide plus Androgen Deprivation Therapy in Oligometastatic Hormone-sensitive Prostate Cancer: A Post Hoc Analysis of ARCHES. Eur Urol 84:229\u2013241","journal-title":"Eur Urol"},{"issue":"16_suppl","key":"2841_CR15","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2025.43.16_suppl.5090","volume":"43","author":"AY Zhang","year":"2025","unstructured":"Zhang\u00a0AY et\u00a0al (2025) 8\u2011year outcomes of enzalutamide versus a non-steroidal anti-androgen for metastatic hormone-sensitive prostate cancer (ENZAMET; ANZUP 1304). J\u00a0Clin Oncol 43(16_suppl):5090","journal-title":"J Clin Oncol"},{"key":"2841_CR16","doi-asserted-by":"publisher","DOI":"10.1200\/EDBK_433126","volume":"44","author":"LM Gudenkauf","year":"2024","unstructured":"Gudenkauf\u00a0LM et\u00a0al (2024) Balancing Hormone Therapy: Mitigating Adverse Effects of Androgen-Deprivation Therapy and Exploring Alternatives in Prostate Cancer Management. Am Soc Clin Oncol Educ Book 44:e433126","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"2841_CR17","doi-asserted-by":"publisher","first-page":"2353","DOI":"10.1016\/S0140-6736(18)32486-3","volume":"392","author":"CC Parker","year":"2018","unstructured":"Parker\u00a0CC et\u00a0al (2018) Systemic Therapy for Advanced or Metastatic Prostate cancer: Evaluation of Drug Efficacy (STAMPEDE) investigators. Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial. Lancet 392:2353\u20132366","journal-title":"Lancet"},{"key":"2841_CR18","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/j.eururo.2024.02.008","volume":"86","author":"NG Nickols","year":"2024","unstructured":"Nickols\u00a0NG et\u00a0al (2024) Systemic and Tumor-directed Therapy for Oligometastatic Prostate Cancer: The SOLAR Phase 2 Trial in De Novo Oligometastatic Prostate Cancer. Eur Urol 86:190\u2013193","journal-title":"Eur Urol"},{"key":"2841_CR19","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1016\/j.eururo.2025.07.006","volume":"88","author":"AD Sherry","year":"2025","unstructured":"Sherry\u00a0AD et\u00a0al (2025) Continuous Androgen Deprivation Therapy with or Without Metastasis-directed Therapy for Oligometastatic Prostate Cancer: The Multicenter Phase 2 Randomized EXTEND Trial. Eur Urol 88:496\u2013509","journal-title":"Eur Urol"},{"key":"2841_CR20","first-page":"172","volume":"114","author":"AJ Templeton","year":"2025","unstructured":"Templeton\u00a0AJ et\u00a0al (2025) Interdisciplinary Swiss Consensus Recommendations on Management of Advanced Prostate Cancer. Praxis 114:172\u2013180","journal-title":"Praxis"},{"key":"2841_CR21","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/S1470-2045(25)00658-8","volume":"27","author":"C Tang","year":"2026","unstructured":"Tang\u00a0C et\u00a0al (2026) Metastasis-directed therapy and standard of care versus standard of care for oligometastatic prostate cancer (WOLVERINE): a\u00a0systematic review and individual patient data meta-analysis from the X\u2011MET collaboration. Lancet Oncol 27:181\u2013190","journal-title":"Lancet Oncol"},{"key":"2841_CR22","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1200\/JCO.2017.75.4853","volume":"36","author":"P Ost","year":"2018","unstructured":"Ost\u00a0P et\u00a0al (2018) Surveillance or Metastasis-Directed Therapy for Oligometastatic Prostate Cancer Recurrence: A Prospective, Randomized, Multicenter Phase II Trial. J\u00a0Clin Oncol 36:446\u2013453","journal-title":"J Clin Oncol"},{"key":"2841_CR23","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1016\/S1470-2045(24)00730-7","volume":"26","author":"G Marvaso","year":"2025","unstructured":"Marvaso\u00a0G et\u00a0al (2025) ADT with SBRT versus SBRT alone for hormone-sensitive oligorecurrent prostate cancer (RADIOSA): a randomised, open-label, phase 2 clinical trial. Lancet Oncol 26:300\u2013311","journal-title":"Lancet Oncol"},{"key":"2841_CR24","doi-asserted-by":"publisher","first-page":"3812","DOI":"10.1200\/JCO-25-01553","volume":"43","author":"AU Kishan","year":"2025","unstructured":"Kishan\u00a0AU et\u00a0al (2025) 177Lu-Prostate-Specific Membrane Antigen Neoadjuvant to Stereotactic Ablative Radiotherapy for Oligorecurrent Prostate Cancer (LUNAR): An Open-Label, Randomized, Controlled, Phase II Study. J\u00a0Clin Oncol 43:3812\u20133821","journal-title":"J Clin Oncol"},{"key":"2841_CR25","doi-asserted-by":"publisher","first-page":"1314","DOI":"10.1056\/NEJMoa1212299","volume":"368","author":"M Hussain","year":"2013","unstructured":"Hussain\u00a0M et\u00a0al (2013) Intermittent versus continuous androgen deprivation in prostate cancer. N\u00a0Engl J Med 368:1314\u20131325","journal-title":"N Engl J Med"},{"key":"2841_CR26","doi-asserted-by":"publisher","first-page":"2450","DOI":"10.1200\/JCO.2008.19.9810","volume":"27","author":"M Hussain","year":"2009","unstructured":"Hussain\u00a0M et\u00a0al (2009) Prostate-specific antigen progression predicts overall survival in patients with metastatic prostate cancer: data from Southwest Oncology Group Trials 9346 (Intergroup Study 0162) and 9916. J\u00a0Clin Oncol 27:2450\u20132456","journal-title":"J Clin Oncol"},{"key":"2841_CR27","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1056\/NEJMoa2510310","volume":"394","author":"ND Shore","year":"2026","unstructured":"Shore\u00a0ND et\u00a0al (2026) Improved Survival with Enzalutamide in Biochemically Recurrent Prostate Cancer. N\u00a0Engl J Med 394:563\u2013575","journal-title":"N Engl J Med"},{"key":"2841_CR28","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.52971","volume":"8","author":"A Holzgreve","year":"2025","unstructured":"Holzgreve\u00a0A et\u00a0al (2025) PSMA-PET\/CT Findings in Patients With High-Risk Biochemically Recurrent Prostate Cancer With No Metastatic Disease by Conventional Imaging. JAMA Netw Open 8:e2452971","journal-title":"JAMA Netw Open"},{"key":"2841_CR29","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1016\/j.euf.2024.06.008","volume":"10","author":"F Turco","year":"2024","unstructured":"Turco\u00a0F et\u00a0al (2024) Is There a Place for De-escalating Therapy in Patients with Metastatic Hormone-sensitive Prostate Cancer? Eur Urol Focus 10:518\u2013521","journal-title":"Eur Urol Focus"},{"key":"2841_CR30","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1391825","volume":"14","author":"G Grisay","year":"2024","unstructured":"Grisay\u00a0G et\u00a0al (2024) EORTC 2238 \u201eDe-Escalate\u201c: a pragmatic trial to revisit intermittent androgen deprivation therapy in the era of new androgen receptor pathway inhibitors. Front Oncol 14:1391825","journal-title":"Front Oncol"}],"container-title":["Die Urologie"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00120-026-02841-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00120-026-02841-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00120-026-02841-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T12:36:37Z","timestamp":1782477397000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00120-026-02841-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,18]]},"references-count":30,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["2841"],"URL":"https:\/\/doi.org\/10.1007\/s00120-026-02841-4","relation":{},"ISSN":["2731-7064","2731-7072"],"issn-type":[{"value":"2731-7064","type":"print"},{"value":"2731-7072","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,18]]},"assertion":[{"value":"16 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"R.\u00a0Cathomas gibt an: Beratungst\u00e4tigkeit f\u00fcr: Astellas, Bayer, Johnson & Johnson, Astra Zeneca, MSD, BMS, Roche, Ipsen, Pfizer.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autor\/-innen keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}